Immunopathogenesis of multiple sclerosis

Annals of Indian Academy of Neurology

Volumn 12, Issue 4, 2009, Pages 215-220

  Racke, Michael K ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Magnetic resonance imaging; Multiple sclerosis; Pathogenesis; Review

Indexed keywords

IMMUNOGLOBULIN G; MYELIN ASSOCIATED GLYCOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN NOGO;

ASTROCYTE; BRAIN CORTEX; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CEREBROSPINAL FLUID; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HUMAN; HYPERGLYCEMIA; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROTON NUCLEAR MAGNETIC RESONANCE; REMYELINIZATION; REVIEW; WHITE MATTER;

EID: 72949116951     PISSN: 09722327     EISSN: 19983549     Source Type: Journal    
DOI: 10.4103/0972-2327.58274     Document Type: Review

References (47)

1. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006;354:942-955
2. Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, et al. Characterizing the mechanisms of progression in multiple sclerosis: Evidence and new hypotheses for future directions. Arch Neurol 2005;62:1345-1356
3. Compston A. The pathogenesis and basis for treatment in multiple sclerosis. Clin Neurol Neurosurg 2004;106:246-248
4. De Keyser J, Zeinstra E, Frohman E. Are astrocytes central players in the pathophysiology of multiple sclerosis? Arch Neurol 2003;60:132-136
5. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients: A marker of activated/memory T cells. J Clin Invest 1998;101:725-730
6. Nikbin B, Bonab MM, Khosravi F, Talebian F. Role of B cells in pathogenesis of multiple sclerosis. Int Rev Neurobiol 2007;79:13-42.
7. Herndon RM. In: Herndon RM, editor. Multiple sclerosis: Immunology, pathology, and pathophysiology. Demos Medical Publishing LLC; 2003.
8. Johnson AJ, Suidan GL, McDole J, Pirko I. The CD8 T cell in multiple sclerosis: Suppressor cell or mediator of neuropathology? Int Rev Neurobiol 2007;79:73-97.
9. McFarland HF, Martin R. Multiple sclerosis: A complicated picture of autoimmunity. Nat Immunol 2007;8:913-919
10. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688
11. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 2004;55:458-468
12. International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis Identified by a genomewide study. N Engl J Med 2007;357:851-862
13. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68:S22-31; discussion S43-54.
14. Waxman SG. Demyelinating diseases--new pathological insights, new therapeutic targets. N Engl J Med 1998;338:323-325
15. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: Relationship to neurologic disability. Curr Opin Neurol 1999;12:295-302. (Pubitemid 29378163)
16. Rovaris M, Gambini A, Gallo A, Falini A, Ghezzi A, Benedetti B, et al. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology 2005;65:1626-1630
17. Gonzenbach RR, Schwab ME. Disinhibition of neurite growth to repair the injured adult CNS: Focusing on Nogo. Cell Mol Life Sci 2008;65:161-176
18. Karnezis T, Mandemakers W, McQualter JL, Zheng B, Ho PP, Jordan KA, et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci 2004;7:736-744
19. Wolswijk G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain 2002;125:338-349
20. John GR, Shankar SL, Shafit-Zagardo B, Massimi A, Lee SC, Raine CS, et al. Multiple sclerosis: Re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 2002;8:1115-1121
21. Williams A, Piaton G, Lubetzki C. Astrocytes--friends or foes in multiple sclerosis? Glia 2007;55:1300-1312
22. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, et al. Interleukin-17 production in central nervous systemin filtrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172:146-155
23. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008;14:337-342
24. Gocke AR, Cravens PD, Ben LH, Hussain RZ, Northrop SC, Racke MK, et al. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 2007;178:1341-1348
25. Haak S, Croxford AL, Dreymborg K, Heppner FL, Pouly S, Becher B, et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inß ammation in mice. J Clin Invest 2009;119:61-69
26. Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, et al. The utility of MRI in suspected MS: Report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2003;61:602-611
27. Simon JH. Update on multiple sclerosis. Radiol Clin North Am 2006;44:79-100.
28. Fisher E, Chang A, Fox RJ, Tkach JA, Svarovsky T, Nakamura K, et al. Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol 2007;62:219-228
29. Zivadinov R, Cox JL. Neuroimaging in multiple sclerosis. Int Rev Neurobiol 2007;79:449-474.
30. Filippi M, Agosta F. Magnetization transfer MRI in multiple sclerosis. J Neuroimaging 2007;17:22S-6S. (Pubitemid 46558264)
31. Rovaris M, Filippi M. Diffusion tensor MRI in multiple sclerosis. J Neuroimaging 2007;17:27S-30S. (Pubitemid 46558265)
32. Rovaris M, Judica E, Gallo A, Benedetti B, Sormani MP, Caputo D, et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain 2006;129:2628-2634
33. De Stefano N, Filippi M. MR spectroscopy in multiple sclerosis. J Neuroimaging 2007;17:31S-5S.
34. Inglese M, Ge Y, Filippi M, Falini A, Grossman RI, Gonen O. Indirect evidence for early widespread gray matter Involvement in relapsing-remitting multiple sclerosis. Neuroimage 2004;21:1825-1829
35. Pulicken M, Gordon-Lipkin E, Balcer LJ, Frohman E, Cutter G, Calabresi PA. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 2007;69:2085-2092 (Pubitemid 350175711)
36. Gordon-Lipkin E, Chodkowski B, Reich DS, Smith SA, Pulicken M, Balcer LJ, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 2007;69:1603-1609
37. Rocca MA, Filippi M. Functional MRI in multiple sclerosis. J Neuroimaging 2007;17:36S-41S.
38. Geurts JJ, Bö L, Pouwels PJ, Castelijns JA, Polman CH, Barkhof F. Cortical lesions in multiple sclerosis: Combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol 2005;26:572-577 (Pubitemid 43085960)
39. Kangarlu A, Bourekas EC, Ray-Chaudhury A, Rammohan KW. Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol 2007;28:262-266
40. Wolansky L. Betaseron vs. copaxone in MS with triple-dose gadolinium and 3-T MRI Endpoints (BECOME): Announcement of final primary study outcome. Presented at: 23rd congress of the European committee for treatment and research in multiple sclerosis (ECTRIMS). Prague, Czech Republic: 2007.
41. Jurewicz A, Matysiak M, Raine CS, Selmaj K. Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. Neurology 2007;68:283-287
42. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008;451:1076-1081
43. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63-66
44. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
45. Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ. Dual PPAR alpha/gamma agonists: Promises and pitfalls in type 2 diabetes. Am J Ther 2007;14:49-62.
46. Diab A, Deng C, Smith JD, Hussain RZ, Phanavanh B, Lovett-Racke AE, et al. Peroxisome proliferator-activated receptor-γ agonist 15-deoxy-Δ 12, 14-PGJ2 ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002;168:2508-2515
47. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, et al. PPARα agonists as therapy for autoimmune disease. J Immunol 2004;172:5790-5798